Navigation Links
FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
Date:2/28/2011

PHILADELPHIA, Feb. 28, 2011 /PRNewswire/ -- Shire plc, (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the use of once-daily INTUNIV® (guanfacine) Extended-Release Tablets as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents ages 6 to 17 as part of a total treatment program. The approval is based on results from a 9-week placebo-controlled study of INTUNIV when given in combination with a stimulant, in children and adolescents with ADHD.(1)

"This approval of INTUNIV for treating ADHD as adjunctive therapy to a stimulant offers physicians a new treatment option for children and adolescents with ADHD who are having a suboptimal response to their current stimulant therapy," said Robert Findling, MD, Director of Child & Adolescent Psychiatry at University Hospitals Case Medical Center and Professor of Psychiatry & Pediatrics at Case Western Reserve University School of Medicine, a lead investigator for the study. "In this study, the once-daily dosing of INTUNIV was effective when taken in the morning or the evening, giving physicians flexibility when it comes to treating their patients with ADHD."

INTUNIV is indicated for the treatment of ADHD as monotherapy and as adjunctive therapy to stimulant medications in children and adolescents ages 6 to 17. The effectiveness of INTUNIV for more than 9 weeks has not been systematically evaluated. The physician electing to use INTUNIV for extended periods should periodically reevaluate its long-term usefulness for the individual patient. INTUNIV is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educati
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves Edarbi to Treat High Blood Pressure
2. FDA Approves EDARBI (azilsartan medoxomil) for the Treatment of Hypertension
3. FDA Approves Product to Prevent Bleeding in People With Rare Genetic Defect
4. FDA Approves First 3-D Mammography Imaging System
5. FDA Approves 1st Pacemaker Designed to Work Safely During Some MRI Exams
6. FDA Approves Hologics Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical
7. FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women
8. FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth
9. FDA Approves Viibryd to Treat Major Depressive Disorder
10. FDA Approves Head Lice Treatment for Children and Adults
11. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 Patterson Medical, formerly the ... PDCO ), is now an independent company with ... Patterson Medical by Madison Dearborn Partners (MDP).  ... for a transition period before rebranding as the ... medicine products.  With the focused resources and expertise ...
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... Novartis, ranibizumab was approved by CFDA to treat wet ... Lucentis, a product of Novartis, is available in the ... self- developed drug for the treatment of wet AMD ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015  Perrigo Company ... that it has completed the acquisition of leading OTC ... at €200 million. The transaction is a clear demonstration ... the Company,s leading European distribution network spanning 36 countries.  ... Joseph C. Papa commented, "We are excited to ...
Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... NEW YORK, Oct. 27 Intercept Pharmaceuticals, Inc., today ... double-blind Phase II clinical trial of INT-747 in ... evaluated the effects of adding one of three doses ... in patients who did not respond adequately to UDCA ...
... Pharmaceuticals, Inc. today announced $4.5 million in Series A and ... complete the company,s ongoing Phase I/IIa trial of BP-GMAX-CD1 in ... for Phase IIb trials. The company anticipates reporting initial results ... new funding brings the total raised to date to $8.5 ...
Cached Medicine Technology:Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis 2Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis 3Bellicum Pharmaceuticals Announces $4.5 Million in New Funding 2
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... to insufficient scrotal support and protection against dribbled urine and sweat. "In order ... Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and President of ... increase acceptance of the chiropractic field in the military. All too often VA hospitals ... Chiropractic was made available to the VA program over a decade ago, the reality ...
(Date:8/29/2015)... NY (PRWEB) , ... August 29, 2015 , ... Next ... end of summer (which astronomically, officially ends on September 22nd this year). For IT ... cyber security hangovers linger on which could prove far more costly than a simple ...
(Date:8/29/2015)... Calgary, AB (PRWEB) , ... August 29, 2015 ... ... congestive heart failure, angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are ... conditions such as angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2
... Cross and its,affiliates and The Children,s Hospital of ... seven-year agreement. A term of this length is,unusual ... history of this key partnership.,The extended contract will ... Children,s Hospital, serving the,special health care needs of ...
... 4 Perrigo Company,(Nasdaq: PRGO ; TASE) ... mg,Omeprazole delayed released tablets to its retail customers. ... dose as Prilosec OTC(R). Under terms,of an agreement ... exclusive marketer and distributor for the store brand ...
... For patients with acute kidney injury (AKI), an external ... injured kidneys and significantly reduces the risk of death, ... May Journal of the American Society of Nephrology. , ... and effective for desperately ill patients with AKI. ...
... DETROIT, March 4 Metro Parent and Henry Ford ... known TV,and movie personality, and best-selling author of Louder ... metro Detroit area. McCarthy will,be the keynote speaker at ... the Troy Hilton, an event designed to educate locals ...
... similar prevalence of adverse drug reactions in the treatment ... likely than their male counterparts to be treated with ... by researchers at Rush University Medical Center. The study ... Gender Medicine. , Developments in disease recognition and novel ...
... ANNAPOLIS, Md., March 4 Dozens of ... gathered in Annapolis today as,the General Assembly ... regulations, protections against identity theft, and the ... visited legislators,offices and attended committee hearings on ...
Cached Medicine News:Health News:Independence Blue Cross and The Children's Hospital of Philadelphia Reach Seven-Year Agreement 2Health News:Independence Blue Cross and The Children's Hospital of Philadelphia Reach Seven-Year Agreement 3Health News:Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets 2Health News:Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets 3Health News:'Renal Assist Device' reduces risk of death from acute kidney failure 2Health News:TV Personality and Best-Selling Author Jenny McCarthy Comes to Detroit to Share Her Story of the Struggles and Triumphs of Raising Her Son, Evan, During a Day-Long Autism Workshop 2Health News:Women are treated less frequently than men with statins, aspirin and beta-blockers 2Health News:Utilities, Long Term Care Bills at Center of 'AARP Day In Annapolis' 2
... is a mini glaucoma ... of filtration surgery for patients ... trabeculectomy, the shunt reduces the ... humor from the anterior chamber ...
... rings, Type 14, 14A and 14C have been ... diameters to accommodate the variations in the size ... capsular tension rings are designed to stabilize the ... a large panel of U.S. ophthalmologists. For ...
Hardee bone rongeur made with the highest quality to meet the exacting standards expected in your surgical specialty....
Traditional design utility pliers have adjustable jaws. Good all purpose plier for handling Steinmann Pins, K-Wires, screws and rods. 10mm jaw tip....
Medicine Products: